Swedish research supports human papillomavirus (HPV) screening:
This article was originally published in Clinica
Executive Summary
The case for human papillomavirus screening is strengthened by recent research from Sweden which shows that the carcinogenic virus can be found in most women who develop cervical cancer. Two-thirds of women who go on to develop cervical cancer have oncogenic HPV in smear samples up to seven years before detection, according to the researchers (Cancer V 77, pp 121-7). Only 11% of smears from women who did not develop cancer had evidence of carcinogenic HPV.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.